Dr. Pal on Adjuvant Therapy of Renal Cell Carcinoma
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).
Today, adjuvant therapy is not a standard of care for localized RCC, though there are studies looking at agents in this space. There are several trials looking at VEGF-directed therapies and it has been demonstrated that patients in the adjuvant setting may not tolerate doses that they would in the metastatic setting.
The only assessment of targeted therapies that has been completed to date is outside the category of VEGF or mTOR inhibition. Girentuximab, which targets CA9, did not have a significant impact on disease-free survival or overall survival.